Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Organovo Holdings Inc Reaches Milestone Ahead of Schedule, Stock Pops

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Organovo Holdings Inc (NYSEMKT: ONVO  ) is a 3-D bioprinting company that has seen its shares pop by as much as 17% today, on a day when the rest of the market is down. What's the reason for this movement, and what does it mean for investors? Read below to find out.

Source: Organovo 

As a publicly traded company, Organovo doesn't have much revenue to brag about. In fact, over the past four quarters, the company has logged only $1.2 million in revenue -- and yet it is currently valued at a ridiculous $750 million.

You won't see valuations like that very often in the public markets. But then again, you won't see too many companies trying to do what this company is attempting either. This year is supposed to be a big one for Organovo, as its first product -- 3-D liver assays -- are set to hit the market before 2015.

In simple terms, these liver assays are 3-D printed liver cells that are supposed to behave just like native liver cells. Pharmaceutical companies can use the cells to test drugs for toxicities and get more reliable results than they can now -- all before applying for FDA approval. The idea is that because the toxicities will show up earlier in the approval process -- or before the process even begins -- the drug companies will save tons of money before going through the laborious and expensive FDA gauntlet.

Hitting a major milestone early
Back in December, I pointed out three things that investors in Organovo needed to watch in 2014. The first was the results of the company's functional validation. Basically, that means the company was testing the cells in-house to see if they responded appropriately to known toxicities.

Source: Organovo 

The results from these tests were expected to be released sometime in March. Following that, Organovo planned to turn over its liver cells to key opinion leaders (KOLs) for feedback in April.

But today, the company announced that the timeline has sped up dramatically. Instead of April, Organovo was able to deliver its first liver tissue to a KOL -- identified as a top research scientist -- in January. The company's Chief Technology Officer also stated, "we have...greatly increased our ability to produce [3-D liver tissues]. By the end of January, we expect to have bioprinted nearly four hundred 3D Liver tissues during the month." 

That also means that instead of these liver assays hitting the market in December 2014, the company now expects for them to be generating revenue before December -- although no specific timeline was given.

What this means for investors
Make no mistake about it, Organovo is a risky and volatile stock. As mentioned above, it is extremely pricey based on traditional metrics.

And yet for long-term investors -- we're talking decades-long -- it's hard to deny the opportunity here. That's why I already own shares of the company. But as of this writing, they comprise less than 1% of my overall holdings.

Though $750 million is a large market cap for the company right now, if it is able to continue bioprinting other types of cells, I think the stock could appreciate noticeably in the future. I'm content to buy in at higher prices when more information is available -- if that's how things pan out.

Investing in more sturdy biotech companies...
Organovo could be a ridiculously lucrative bet on biotechnology, but its by no means a guaranteed winner.

The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (3) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 29, 2014, at 11:27 AM, badeconomy wrote:

    Great analysis, another article that has an accurate approach to onvo's strategy,value, potential, unique technology and competition. But I do not agree that for short or LONG term investors it would take decades to profit from their investment in onvo, the necessary technology is advancing/improving at the speed which was hard to imagine just 6 month ago.

  • Report this Comment On January 29, 2014, at 11:38 AM, TMFCheesehead wrote:


    Fair enough, but if we set our sights that far in the distance, anything that comes between now and then is just gravy! In other words, let's set our expectations LONG, and be pleasantly surprised if they come to fruition sooner.

    Brian Stoffel

  • Report this Comment On January 29, 2014, at 11:39 AM, MelissainVA wrote:


    I appreciate the timeliness of this analysis. ONVO will either fundamentally change the game of drug testing or it will be a brilliant failure. Either way the small percentage of my portfolio dedicated to it and I are committed to the wild ride ahead!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2814566, ~/Articles/ArticleHandler.aspx, 8/30/2015 10:35:18 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Stoffel

Brian Stoffel has been a Fool since 2008, and a financial journalist for the Motley Fool since 2010. He tends to follow the investment strategies of Fool-founder David Gardner, looking for the most innovative companies driving positive change for the future.

Today's Market

updated 2 days ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
ONVO $2.54 Up +0.04 +1.60%